IGM Biosciences, Inc. (IGMS)
- Previous Close
7.70 - Open
7.76 - Bid 7.92 x 200
- Ask 7.98 x 100
- Day's Range
7.75 - 8.60 - 52 Week Range
3.81 - 17.70 - Volume
692,933 - Avg. Volume
263,585 - Market Cap (intraday)
467.941M - Beta (5Y Monthly) 0.25
- PE Ratio (TTM)
-- - EPS (TTM)
-4.71 - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.22
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
igmbio.comRecent News: IGMS
Performance Overview: IGMS
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IGMS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IGMS
Valuation Measures
Market Cap
452.66M
Enterprise Value
155.49M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
189.11
Price/Book (mrq)
2.23
Enterprise Value/Revenue
73.00
Enterprise Value/EBITDA
-0.61
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.91%
Return on Equity (ttm)
-100.48%
Revenue (ttm)
2.13M
Net Income Avi to Common (ttm)
-246.42M
Diluted EPS (ttm)
-4.71
Balance Sheet and Cash Flow
Total Cash (mrq)
337.68M
Total Debt/Equity (mrq)
19.93%
Levered Free Cash Flow (ttm)
-121.96M